RUNX2 and plasma cell myeloma: Recently, Trotter et al. demonstrated that RUNX2 is tightly involved in the promotion of multiple myeloma growth, survival and progression through the up-regulation of Akt/beta-catenin/survivin pro-oncogenic signaling pathway [43].